External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Paula Jimenez-FonsecaAlberto Carmona-BayonasAlba Martinez-TorronMaria AlsinaAna CustodioOlbia SerraDiego Cacho LavinMaría Luisa LimónTamara SauriFlora LópezLaura VisaMónica GranjaNieves Martínez-LagoVirginia ArrazubiRosario Vidal TocinoRaquel HernandezGema AguadoJuana María CanoAlfonso Martín CarniceroMonserrat MangasPaola PimentelAna Fernández MontesIsmael Macias DeclaraFederico LongoAvinash RamchandaniMarta Martín RichardAlicia HurtadoAitor AzkarateCarolina Hernández PérezRaquel SerranoJavier Gallegonull nullPublished in: Therapeutic advances in medical oncology (2021)
We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX-trastuzumab in clinical practice and point toward a possible benefit of FOLFOX-trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials.